Marisa Medina, PhD
Associate Professor
Pediatrics
School of Medicine

Education & Training

Show all (3) Hide

• Diversity, Equity, and Inclusion Champion Training University of California 03/2021
• postdoctoral fellowship Pharmacogenetics Children's Hospital Oakland Research Institute
• PhD Genetics UC Davis

Websites

Show all (1) Hide

• Medina Lab (medinalab.ucsf.edu)

Grants and Projects

Show all (9) Hide

• TMEM55B as a molecular determinant of NAFLD., NIH/NIDDK, 2023-2025
• Genetic Regulation of Nonalcoholic Fatty Liver Disease, NIH, 2021-2025
• iPSCs as a screening tool to predict risk of nonalcoholic fatty liver disease, CIRM, 2021-2023
• The Role of Phosphatidylinositides in Lipid Metabolism, NIH, 2020-2021
• Pharmacogenomics of Statin Therapy, NIH/NIGMS, 2015-2021
• Functional Dissection of the 19p13.11 Haplotype, NIH, 2016-2017
• Pharmacogenomics and Risk of Cardiovascular Disease, NIH, 2001-2016
• Alternative Splicing in Regulation of Cholesterol Synthesis and Uptake, NIH, 2010-2015
• Pharmacogenomics and Risk of Cardiovascular Disease, NIH, 2001-2010

Publications (46)

Top publication keywords:
Alternative SplicingHydroxymethylglutaryl-CoA Reductase InhibitorsHep G2 CellsSimvastatinPseudogenesChitinasesCholesterolSerpinsReceptors, LDLInduced Pluripotent Stem CellsCholesterol, LDLPhosphoinositide PhosphatasesHydroxymethylglutaryl CoA ReductasesPhosphatidylinositol 4,5-DiphosphateLipid Metabolism

• Participant-derived cell line transcriptomic analyses and mouse studies reveal a role for ZNF335 in plasma cholesterol statin response.
  bioRxiv : the preprint server for biology 2023 Theusch E, Ting FY, Qin Y, Stevens K, Naidoo D, King SM, Yang N, Orr J, Han BY, Cyster JG, Chen YI, Rotter JI, Krauss RM, Medina MW
• Development and application of an algorithm for statin-induced myopathy based on electronic health record-derived structured elements.
  medRxiv : the preprint server for health sciences 2023 Oni-Orisan A, Lu M, Peng JA, Krauss RM, Iribarren C, Medina MW
• Mechanism of the Regulation of Plasma Cholesterol Levels by PI(4,5)P2.
  Advances in experimental medicine and biology 2023 Qin Y, Medina MW
• Undifferentiated Induced Pluripotent Stem Cells as a Genetic Model for Nonalcoholic Fatty Liver Disease.
  Cellular and molecular gastroenterology and hepatology 2022 Muñoz A, Theusch E, Kuang YL, Nalula G, Peaslee C, Dorlhiac G, Landry MP, Streets A, Krauss RM, Iribarren C, Mattis AN, Medina MW
• Modest effect of statins on fasting glucose in a longitudinal electronic health record based cohort.
  Cardiovascular diabetology 2022 Haldar T, Oni-Orisan A, Hoffmann TJ, Schaefer C, Iribarren C, Krauss RM, Medina MW, Risch N

Show all (41 more) Hide

• A gene-diet interaction controlling relative intake of dietary carbohydrates and fats.
  Molecular metabolism 2022 Nelson NG, Wu L, Maier MT, Lam D, Cheang R, Alba D, Huang A, Neumann DA, Hill T, Vagena E, Barsh GS, Medina MW, Krauss RM, Koliwad SK, Xu AW
• Doxycycline Significantly Enhances Induction of Induced Pluripotent Stem Cells to Endoderm by Enhancing Survival Through Protein Kinase B Phosphorylation.
  Hepatology (Baltimore, Md.) 2021 Peaslee C, Esteva-Font C, Su T, Munoz-Howell A, Duwaerts CC, Liu Z, Rao S, Liu K, Medina M, Sneddon JB, Maher JJ, Mattis AN
• Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin.
  Clinical pharmacology and therapeutics 2021 Lu B, Sun L, Seraydarian M, Hoffmann TJ, Medina MW, Risch N, Iribarren C, Krauss RM, Oni-Orisan A
• A unified framework identifies new links between plasma lipids and diseases from electronic medical records across large-scale cohorts.
  Nature genetics 2021 Veturi Y, Lucas A, Bradford Y, Hui D, Dudek S, Theusch E, Verma A, Miller JE, Kullo I, Hakonarson H, Sleiman P, Schaid D, Stein CM, Edwards DRV, Feng Q, Wei WQ, Medina MW, Krauss RM, Hoffmann TJ, …
• Genetic variants modulate gene expression statin response in human lymphoblastoid cell lines.
  BMC genomics 2020 Theusch E, Chen YI, Rotter JI, Krauss RM, Medina MW
• Phosphatidylinositol-(4,5)-Bisphosphate Regulates Plasma Cholesterol Through LDL (Low-Density Lipoprotein) Receptor Lysosomal Degradation.
  Arteriosclerosis, thrombosis, and vascular biology 2020 Qin Y, Ting F, Kim MJ, Strelnikov J, Harmon J, Gao F, Dose A, Teng BB, Alipour MA, Yao Z, Crooke R, Krauss RM, Medina MW
• The impact of adjusting for baseline in pharmacogenomic genome-wide association studies of quantitative change.
  NPJ genomic medicine 2020 Oni-Orisan A, Haldar T, Ranatunga DK, Medina MW, Schaefer C, Krauss RM, Iribarren C, Risch N, Hoffmann TJ
• GeneFishing to reconstruct context specific portraits of biological processes.
  Proceedings of the National Academy of Sciences of the United States of America 2019 Liu K, Theusch E, Zhou Y, Ashuach T, Dose AC, Bickel PJ, Medina MW, Huang H
• Evaluation of commonly used ectoderm markers in iPSC trilineage differentiation.
  Stem cell research 2019 Kuang YL, Munoz A, Nalula G, Santostefano KE, Sanghez V, Sanchez G, Terada N, Mattis AN, Iacovino M, Iribarren C, Krauss RM, Medina MW
• Characterization of Statin Low-Density Lipoprotein Cholesterol Dose-Response Using Electronic Health Records in a Large Population-Based Cohort.
  Circulation. Genomic and precision medicine 2018 Oni-Orisan A, Hoffmann TJ, Ranatunga D, Medina MW, Jorgenson E, Schaefer C, Krauss RM, Iribarren C, Risch N
• ZNF542P is a pseudogene associated with LDL response to simvastatin treatment.
  Scientific reports 2018 Kim K, Theusch E, Kuang YL, Dose A, Mitchel K, Cubitt C, Chen YI, Krauss RM, Medina MW
• A large electronic-health-record-based genome-wide study of serum lipids.
  Nature genetics 2018 Hoffmann TJ, Theusch E, Haldar T, Ranatunga DK, Jorgenson E, Medina MW, Kvale MN, Kwok PY, Schaefer C, Krauss RM, Iribarren C, Risch N
• Generalized correlation measure using count statistics for gene expression data with ordered samples.
  Bioinformatics (Oxford, England) 2018 Wang YXR, Liu K, Theusch E, Rotter JI, Medina MW, Waterman MS, Huang H, Stegle O
• Human genetic variation in VAC14 regulates Salmonella invasion and typhoid fever through modulation of cholesterol.
  Proceedings of the National Academy of Sciences of the United States of America 2017 Alvarez MI, Glover LC, Luo P, Wang L, Theusch E, Oehlers SH, Walton EM, Tram TTB, Kuang YL, Rotter JI, McClean CM, Chinh NT, Medina MW, Tobin DM, Dunstan SJ, Ko DC
• SUGP1 is a novel regulator of cholesterol metabolism.
  Human molecular genetics 2016 Kim MJ, Yu CY, Theusch E, Naidoo D, Stevens K, Kuang YL, Schuetz E, Chaudhry AS, Medina MW
• RP1-13D10.2 Is a Novel Modulator of Statin-Induced Changes in Cholesterol.
  Circulation. Cardiovascular genetics 2016 Mitchel K, Theusch E, Cubitt C, Dosé AC, Stevens K, Naidoo D, Medina MW
• Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations.
  Journal of cardiovascular pharmacology 2015 Luzum JA, Theusch E, Taylor KD, Wang A, Sadee W, Binkley PF, Krauss RM, Medina MW, Kitzmiller JP
• GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals.
  Cell metabolism 2015 Luzum JA, Kitzmiller JP, Isackson PJ, Ma C, Medina MW, Dauki AM, Mikulik EB, Ochs-Balcom HM, Vladutiu GD
• Ancestry and other genetic associations with plasma PCSK9 response to simvastatin.
  Pharmacogenetics and genomics 2014 Theusch E, Medina MW, Rotter JI, Krauss RM
• CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.
  Pharmacogenetics and genomics 2014 Kitzmiller JP, Luzum JA, Baldassarre D, Krauss RM, Medina MW
• Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation.
  Genome biology 2014 Kim K, Bolotin E, Theusch E, Huang H, Medina MW, Krauss RM
• Transmembrane protein 55B is a novel regulator of cellular cholesterol metabolism.
  Arteriosclerosis, thrombosis, and vascular biology 2014 Medina MW, Bauzon F, Naidoo D, Theusch E, Stevens K, Schilde J, Schubert C, Mangravite LM, Rudel LL, Temel RE, Runz H, Krauss RM
• Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines.
  Pharmacogenomics 2014 Brown CC, Havener TM, Medina MW, Jack JR, Krauss RM, McLeod HL, Motsinger-Reif AA
• Statin-induced changes in gene expression in EBV-transformed and native B-cells.
  Human molecular genetics 2013 Bolotin E, Armendariz A, Kim K, Heo SJ, Boffelli D, Tantisira K, Rotter JI, Krauss RM, Medina MW
• HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism.
  Human molecular genetics 2013 Yu CY, Theusch E, Lo K, Mangravite LM, Naidoo D, Kutilova M, Medina MW
• A statin-dependent QTL for GATM expression is associated with statin-induced myopathy.
  Nature 2013 Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, Mecham BH, Howie B, Shim H, Naidoo D, Feng Q, Rieder MJ, Chen YD, Rotter JI, Ridker PM, Hopewell JC, Parish S, Armitage J, …
• Alternative splicing in the regulation of cholesterol homeostasis.
  Current opinion in lipidology 2013 Medina MW, Krauss RM
• A common polymorphism in the LDL receptor gene has multiple effects on LDL receptor function.
  Human molecular genetics 2013 Gao F, Ihn HE, Medina MW, Krauss RM
• ATHENA: a tool for meta-dimensional analysis applied to genotypes and gene expression data to predict HDL cholesterol levels.
  Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 2013 Holzinger ER, Dudek SM, Frase AT, Krauss RM, Medina MW, Ritchie MD
• Multivariate methods and software for association mapping in dose-response genome-wide association studies.
  BioData mining 2012 Brown CC, Havener TM, Medina MW, Krauss RM, McLeod HL, Motsinger-Reif AA
• RHOA is a modulator of the cholesterol-lowering effects of statin.
  PLoS genetics 2012 Medina MW, Theusch E, Naidoo D, Bauzon F, Stevens K, Mangravite LM, Kuang YL, Krauss RM
• A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT.
  Pharmacogenetics and genomics 2012 Brown CC, Havener TM, Medina MW, Auman JT, Mangravite LM, Krauss RM, McLeod HL, Motsinger-Reif AA
• Cardiovascular pharmacogenomics.
  Circulation research 2011 Roden DM, Johnson JA, Kimmel SE, Krauss RM, Medina MW, Shuldiner A, Wilke RA
• Coordinately regulated alternative splicing of genes involved in cholesterol biosynthesis and uptake.
  PloS one 2011 Medina MW, Gao F, Naidoo D, Rudel LL, Temel RE, McDaniel AL, Marshall SM, Krauss RM
• PharmGKB: very important pharmacogene--HMGCR.
  Pharmacogenetics and genomics 2011 Medina MW, Sangkuhl K, Klein TE, Altman RB
• The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy.
  Discovery medicine 2010 Medina MW
• Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin.
  Arteriosclerosis, thrombosis, and vascular biology 2010 Mangravite LM, Medina MW, Cui J, Pressman S, Smith JD, Rieder MJ, Guo X, Nickerson DA, Rotter JI, Krauss RM
• Pharmacogenomic discovery using cell-based models.
  Pharmacological reviews 2009 Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, McLeod H, Dolan ME
• The role of HMGCR alternative splicing in statin efficacy.
  Trends in cardiovascular medicine 2009 Medina MW, Krauss RM
• Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin.
  Circulation 2008 Medina MW, Gao F, Ruan W, Rotter JI, Krauss RM
• Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment.
  Circulation 2008 Krauss RM, Mangravite LM, Smith JD, Medina MW, Wang D, Guo X, Rieder MJ, Simon JA, Hulley SB, Waters D, Saad M, Williams PT, Taylor KD, Yang H, Nickerson DA, Rotter JI